Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria
Archives of Microbiology · 2026
DOI: 10.1007/s00203-026-04723-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Microbiology, 2026. Verfasst von Prince Joshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Microbiology and Immunology Division, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow, UP, 226…. Hauptthemen laut MEDLINE: Neuroprotective Agents, Malaria, Cerebral, Plasmodium falciparum, Antimalarials. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Department of Biotechnology, Ministry of Science and Technology, India, University Grants Commission.
Abstract (Originalsprache)
Cerebral malaria (CM) remains one of the most severe complications of Plasmodium falciparum infection, often leading to death within days and leaving survivors with lasting cognitive damage. Since current treatments target the parasite but offer little to no neuroprotection, we explored whether existing neuroprotective drugs could help fill this gap. Six clinically-approved drugs, viz. topiramate, rasagiline, vinpocetine, cilostazol, piracetam, and rivastigmine were tested for both antimalarial and anti-cerebral malaria activity. Screening against P. falciparum in vitro showed that vinpocetine, cilostazol, and rivastigmine effectively inhibited parasite growth, without causing toxicity in Vero or BB19 cell lines or in human red blood cells. In a mouse model of experimental CM (Plasmodium berghei ANKA-infected C57BL/6 mice), early oral treatment with cilostazol, piracetam, or rivastigmine delayed the onset of CM symptoms and significantly improved survival compared to untreated controls. When treatment was initiated after the first neurological signs, only the combination of rivastigmine with the fast-acting antimalarial α/β-arteether markedly improved outcomes, including parasite clearance and extended survival, compared to either treatment alone. Overall, these results suggest that combining rivastigmine with α/β-arteether may represent a practical and low-cost adjunct therapy for CM. Further mechanistic and clinical studies will be essential to confirm these findings and assess long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Microbiology and Immunology Division, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow, UP, 226 031, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, UP, 201 002, India.
- Division of Neuroscience and Ageing biology, CSIR-Central Drug Research Institute, Lucknow, UP, India.
- Molecular Microbiology and Immunology Division, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow, UP, 226 031, India. renu1113@rediffmail.com.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, UP, 201 002, India. renu1113@rediffmail.com.
Förderung
- Council of Scientific and Industrial Research, India
- Department of Biotechnology, Ministry of Science and Technology, India
- University Grants Commission
Zitieren
APA
Joshi, P., Shaham, S. H., Shivahare, R., Yadav, K., Sharma, A., Parul, Shukla, S., & Tripathi, R. (2026). Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria. Archives of Microbiology. https://doi.org/10.1007/s00203-026-04723-x
Vancouver
Joshi P, Shaham SH, Shivahare R, Yadav K, Sharma A, Parul, et al. Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria. Archives of Microbiology. 2026. doi:10.1007/s00203-026-04723-x
BibTeX
@article{Joshi2026,
author = {Joshi, Prince and Shaham, Salique Hassan and Shivahare, Rahul and Yadav, Kanchan and Sharma, Anamika and Parul and Shukla, Shubha and Tripathi, Renu},
title = {Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria},
journal = {Archives of Microbiology},
year = {2026},
doi = {10.1007/s00203-026-04723-x}
}
EUVIMED